Name
GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.
Date & Time
Friday, December 13, 2024
Speakers
Virtual Session Link
Total Minutes
11:11
OnDemand Video URL